Holen Sie sich die Stockscreener-App
21.59
20.05%
-5.14
Tyra Biosciences Inc Aktie (TYRA) Neueste Nachrichten
Why Is Tyra Biosciences Stock Sinking Wednesday? - Benzinga
Tyra Biosciences (TYRA) Shares Plunge 22% as Bladder Cancer Drug Trial Falls Short - Blockonomi
Why This Biotech Stock Just Plummeted To A 10-Month Low - Investor's Business Daily
Tyra reports 79% response rate in Phase 2 cancer trial - grafa.com
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress - barrons.com
Tyra Biosciences stock tumbles 30% on phase 2 trial results By Investing.com - Investing.com Australia
Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data - finance.yahoo.com
Why is Tyra Biosciences stock plunging today? - Investing.com
Tyra drops after mid-stage trial data for lead asset in bladder cancer - Seeking Alpha
Tyra Bioscience Reports Promising Phase 2 Dabogratinib Data - TipRanks
Tyra Biosciences reports positive Phase 2 SURF302 results, 60 mg QD chosen for registrational adjuvant plan - TradingView
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib - PR Newswire
We're Hopeful That Tyra Biosciences (NASDAQ:TYRA) Will Use Its Cash Wisely - Moomoo
Tyra Biosciences to present at Cantor Global He... - Pluang
Tyra Biosciences sets virtual chat, investor meetings Sept. 9 - Stock Titan
A Quick Look at Today's Ratings for TYRA BIOSCIENCES, INC.(TYRA.US), With a Forecast Between $39 to $56 - Moomoo
Piper Sandler reiterates Tyra Biosciences stock rating ahead of data By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Tyra Biosciences stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Tyra Biosciences stock rating at buy - Investing.com
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $39 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Tyra Biosciences downgraded to Hold ahead of ke... - Pluang
Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts - Seeking Alpha
TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout - Asianet Newsable
Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug - Seeking Alpha
Initial results for an oral bladder cancer drug will be discussed Sept. 9 - Stock Titan
How Tyra Biosciences Inc. (TYRA) Affects Rotational Strategy Timing - Stock Traders Daily
Tyra Biosciences draws industry focus with IR NMIBC research at IBCG26 retreat - Traders Union
Tyra Biosciences (TYRA): Can Dabogratinib Redefine FGFR3-Driven Bladder Cancer? - RTTNews
Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Tyra (TYRA) Results Check: EPS Falls Short of Its Estimate in the Current Update; Post-Earnings: The Market Price Moves 0.65% Higher in the Latest ReadingFinancial Data - vinanet.vn
Tyra’s one-drug, three-indication bet nears its first phase 2 test - Pharma Voice
Farallon Capital Management Slashes Tyra Biosciences (TYRA) Stak - GuruFocus
Tyra Biosciences Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Tyra Biosciences tests innovative therapy in SURF302 for intermediate-risk bladder cancer - Traders Union
Tyra Biosciences (NASDAQ: TYRA): What Comes Next for Its Pipeline? - Kalkine Media
Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 6.2%Time to Buy? - MarketBeat
TYRA Q2 2026 Earnings: EPS Miss Slightly Overshadowed by 6.98% Share AdvanceBasic EPS Analysis - vinanet.vn
TYRA Q2 2026 Earnings: EPS Misses Estimates by 4.14% as Shares Gain 1.08%Healthcare Earnings Report - vinanet.vn
TYRA Q2 2026 Earnings: Wider-than-Expected Loss of -$0.69 per Share, Yet Stock Rises 1.08%Dividend Growth Analysis - vinanet.vn
Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA - MarketBeat
TYRA Biosciences (TYRA) holder reports 3.55M-share, 6% beneficial stake - Stock Titan
Tyra Biosciences examines FGFR3 gene impact on cell growth disorders - Traders Union
Farallon group trims Tyra Biosciences (TYRA) holdings to 6,000 shares, 0% stake - Stock Titan
Avoiding Lag: Real-Time Signals in (TYRA) Movement - Stock Traders Daily
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.82, Implies 94% Upside - TradingView
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $39 - Moomoo
BofA Adjusts Price Target on Tyra Bioscience to $39 From $42 - marketscreener.com
TYRA's dabogratinib trial in 2026 could validat... - Pluang
Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet (NASDAQ:TYRA) - Seeking Alpha
HC Wainwright Brokers Lower Earnings Estimates for TYRA - MarketBeat
Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TYRA Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued Pipeline InvestmentFinancial Health Score - vinanet.vn
Tyra Biosciences (TYRA) Projected to Announce Earnings on Thursday - MarketBeat
Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
BlackRock, Inc. Expands Tyra Biosciences (TYRA) Stake with Strat - GuruFocus
Jefferies Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42 - Moomoo
TYRA Shares Drop Amid Market Volatility; Price-to-Sales Highligh - GuruFocus
Wedbush Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $53 - Moomoo
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down Following Weak Earnings - marketbeat.com
William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - Moomoo
Tyra Biosciences (NASDAQ:TYRA) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Tyra Biosciences : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Tyra Biosciences 2Q 2026: Net loss $45.6M, EPS $(0.69) — 10-Q Summary - TradingView
Tyra Biosciences Q2 net loss widens on higher R&D expenses - TradingView
Tyra Biosciences posts Q2 2026 net loss $45.6M; cash $353.9M, runway into 2H 2028 - TradingView
TYRA: Phase 2 trials progress, strong cash runway, and higher R&D drive increased net loss - TradingView
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):